Tract Bio

Tract Bio is a biotechnology company discovering and developing novel therapies to transform the treatment of cancer and inflammatory disease. The Company’s breakthrough stem cell discovery platform, stemECHO™, allows for reliable, high-volume generation of pure stem cell libraries in their ground-state while preserving the functional, genetic and epigenetic integrity of the original stem cell. The stemECHO™ platform has identified disease-associated stem cells in cancer and inflammatory diseases, including potential treatments for esophageal adenocarcinoma, lung, ovarian, pancreatic and gastric cancer, as well as COPD, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis and Crohn’s Disease. Tract is advancing TP-101, a novel drug combination identified using stemECHO™ that targets a common mechanism among disease-associated stem cells in cancer. The Company is also developing novel therapies for inflammatory diseases.